IPO Boutique

Compass Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...



For IPO Boutique's "scale of 1 to 5" BUY rating on Compass Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Compass Therapeutics, Inc.CMPX -
NASDAQ
Postponed $0.00 $0.00Postponed10/13/2020
Citigroup, Credit Suisse, Stifel
Co-Manager(s):
Raymond James
Health Care
Filing(s):

Filed 2020-10-19
Terms Added 2020-11-09



About Compass Therapeutics, Inc. (adapted from Compass Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "CMPX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved